A Phase 3 interventional study of Soy-based RUTF and Soy-maize-sorghum-based RUTF in Severe Acute Malnutrition, Moderate Acute Malnutrition and Wasting, sponsored by International Food Policy Research Institute. Completed at 1 site in Burkina Faso. Open to participants aged 6 Months to 59 Months. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by International Food Policy Research Institute · Phase 3, Interventional, and Treatment
Acute malnutrition is the most life-threatening form of undernutrition. Moderate and severe acute malnutrition (MAM, SAM) are effectively treated with ready-to-use therapeutic foods (RUTFs) but there is a need to lower the cost of treatment and improve treatment regimens to reduce risk of relapse MAM/SAM episodes following recovery. The currently used standard formulation of RUTF contains peanuts and dairy, which pose problems due to their high cost, the need to import ingredients to the Global South (in the case of dairy), and risk of aflatoxin (in the case of peanuts). Before alternative formulations of RUTF can be recommended, however, there is the need for data on the efficacy of these formulations on recovery rates and to what extent recovery is sustainable. Sustainable recovery implies a lower rate of post-treatment relapse.
The study objectives are as follows: (1) To assess the non-inferiority of soy-maize-sorghum (SMS-) RUTF and soy-based (S-) RUTF on treatment recovery to standard RUTF; (2) To assess the superiority of SMS-RUTF and S- RUTF on post-recovery relapse compared to standard RUTF; (3) To assess the costs of a treatment course of SMS-RUTF, S-RUTF, and standard RUTF; (4) To assess the effect of SMS-RUTF and S-RUTF on microbiome composition and intestinal inflammation
The investigators will conduct a facility-based, individually randomized controlled trial with three arms allocated in a 1:1:1 allocation ratio in 30 health facilities (Centre de Santé et Promotion Sociale [CSPS]) in Burkina Faso. The investigators will randomize 1080 children with MAM and 1080 children with uncomplicated SAM 6-59 months of age to receive treatment with one of the following RUTFs: (1) standard of care, milk- and peanut-based RUTF (control group); (2) SMS-RUTF free of milk and peanuts and high in fiber (intervention 1); or (3) S-RUTF free of milk and peanuts (intervention 2). Children will be enrolled upon presentation to facilities for MAM or uncomplicated SAM treatment. Follow up visits will be weekly during treatment for SAM children and bi-weekly during treatment for MAM children, and monthly for 3 months following discharge from treatment. The primary study outcomes include, among others, anthropometric recovery at discharge (a non-inferiority analysis) and relapse to MAM or SAM within the 3 months following recovery (a superiority analysis). The investigators will employ an activity-based micro-costing approach to collect cost data on the direct and indirect medical costs, opportunity costs to caregivers, personnel, and overheads associated with outpatient MAM or SAM treatment. Fecal samples will be collected from children at a subset of facilities (5 facilities, \~60 children per treatment arm), at enrollment (initiation of treatment), discharge from treatment, and 3-months post-discharge.
Exclusion Criteria:
This is the control arm of the trial, in which children will receive the standard RUTF product for treatment of acute malnutrition
Dietary Supplement: Standard RUTF
This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-based RUTF
Dietary Supplement: Soy-based RUTF
This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-maize-sorghum-based RUTF
Dietary Supplement: Soy-maize-sorghum-based RUTF
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
Anthropometric recovery
Weight-for-length z-score (WLZ) ≥ -2 and middle upper arm circumference (MUAC) ≥ 125 mm and absence of bilateral pitting edema for two consecutive visits
Time frame: At discharge, which is up to 12 weeks after admission
Default from treatment
Child is absent for two consecutive visits, declared a defaulter on the second visit
Time frame: During treatment, which is up to 12 weeks after admission
Relapse to wasting
A new episode of wasting (defined as weight-for-length/height z-score \[WLZ/WHZ\] \< -2 or middle upper arm circumference \[MUAC\] \< 125 mm or presence of bilateral pitting edema) within the 3-month period following recovery from the index wasting episode, among children who recovered from their index episode
Time frame: Within 3 months post-discharge
Transfer to inpatient treatment
Referral or admission to hospital for inpatient treatment during the treatment course
Time frame: During treatment, which is up to 12 weeks after admission
Weight gain
Change in child's weight (gram/kilogram/day) between weight on day of admission to treatment and day of discharge
Time frame: During treatment, which is up to 12 weeks after admission
Non-response to treatment
Any of the following criteria are met: Absence of weight gain after 5 weeks or at the third visit; weight loss for more than 4 weeks in the program or at the second visit; loss of more than 5% of body weight compared to admission weight at any time; or anthropometric recovery criteria not met after 3 months of follow-up in treatment
Time frame: During treatment, which is up to 12 weeks after admission
Adherence to treatment services
Caregiver attends the recommended schedule of visits and receive ready-to-use therapeutic foods (RUTF) supply
Time frame: During treatment, which is up to 12 weeks after admission
Length of stay
The number of days between the day the child is admitted to treatment and the day the child is determined to be recovered and thus discharged from treatment
Time frame: During treatment, which is up to 12 weeks after admission
Anthropometry
Weight-for-length/height z-score (WLZ/WHZ), middle upper arm circumference (MUAC), weight, height/length, length/height-for-age z-score (LAZ/HAZ) and weight-for-age z-score (WAZ)
Time frame: At discharge, which is up to 12 weeks after admission
Relapse to MAM
A new episode of MAM (weight-for-length/height z-score \[WLZ/WHZ\] \<-2 and ≥-3, or middle upper arm circumference \[MUAC\] \<125 mm and ≥115 mm) within the 3-month period following recovery from the index wasting episode
Time frame: Within 3 months post-discharge
Relapse to SAM
A new episode of SAM (weight-for-length/height z-score \[WLZ/WHZ\] \< -3 or middle upper arm circumference \[MUAC\] \< 115 mm or presence of bilateral pitting edema) within the 3-month period following recovery from the index wasting episode
Time frame: Within 3 months post-discharge
Anthropometry
Weight-for-length/height z-score (WLZ/WHZ), middle upper arm circumference (MUAC), weight, height/length, length/height-for-age z-score (LAZ/HAZ) and weight-for-age z-score (WAZ)
Time frame: At 3 months post-discharge
Hemoglobin
Hemoglobin concentration (grams/liter)
Time frame: At discharge, which is up to 12 weeks after admission
Hemoglobin
Hemoglobin concentration (grams/liter)
Time frame: At 3 months post-discharge
Morbidity
Indication of morbidity (acute respiratory infections, diarrhea, fever, or malaria) on health center card
Time frame: During treatment, which is up to 12 weeks after admission
Anemia
Hemoglobin concentration \< 105 gram/liter for children 6-23 months of age Hemoglobin concentration \< 110 gram/liter for children 24-59 months of age
Time frame: At discharge, which is up to 12 weeks after admission
Anemia
Hemoglobin concentration \< 110 gram/liter
Time frame: At 3 months post-discharge
Mortality
Child has deceased
Time frame: During treatment, which is up to 12 weeks after admission, or during the 3-month post-discharge follow up
Acceptability
Observed dose intake/consumed (grams)
Time frame: After 7 days of product trial
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — In accordance with the International Food Policy Research Institute's policy on research data management and open access, at the time of publication of scientific articles presenting results, the fully anonymized databases will become a public good and will be made available to the scientific community, government, and partners.
Supporting information: Study protocol, Sap
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Food Policy Research Institute